Fellowship · Durham, NC
Sponsored by Duke University Hospital
Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia.
Nature · 2024 · 102 citations · Dwight Koeberl
The Global ALPL gene variant classification project: Dedicated to deciphering variants.
Bone · 2024 · 56 citations · Priya Kishnani
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
The Lancet. Neurology · 2021 · 153 citations · Priya Kishnani
Targeted long-read sequencing identifies missing disease-causing variation.
American journal of human genetics · 2021 · 181 citations · Priya Kishnani
In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe's Disease.
The New England journal of medicine · 2022 · 96 citations · Jennifer Cohen, Priya Kishnani
Glycogen storage diseases.
Nature reviews. Disease primers · 2023 · 72 citations · Priya Kishnani
Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry.
Orphanet journal of rare diseases · 2024 · 25 citations · Priya Kishnani
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
The Lancet. Neurology · 2021 · 110 citations · Priya Kishnani